Compare AstraZeneca plc (AZN) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Quantumscape Corp — how do they compare? AstraZeneca plc trades at $168.72 (market cap $253.13B), while Quantumscape Corp trades at $6.62 (market cap $3.95B). The key difference: AstraZeneca plc is far larger — about 64.1× Quantumscape Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| AZN | QS | |
|---|---|---|
Market Cap | $253.13B | $3.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $18.44 |
52-Week Low | $137.44 | $5.96 |
Enterprise Value | $279.37B | $3.11B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
QuantumScape (QS) trades at $6.28, down 4.56% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05M in 2025 and relies on financing cash flows to fund operations. Recent news highlights a joint research agreement with Honda, providing a potential catalyst for its solid-state battery technology development.
The outlook remains speculative with high execution risks as QS transitions from R&D to commercialization. Analyst sentiment is cautious with 73% hold ratings. Investment opportunity hinges on successful battery commercialization, but risks include persistent losses, competitive threats, and reliance on external funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
